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Abstract: Exercise-induced asthma/exercise-induced bronchospasm (EIA/EIB) is a prevalent
and clinically important disease affecting young children through older adulthood. These
terms are often used interchangeably and the differences are not clearly defined in the
literature. The pathogenesis of EIA/EIB may be different in those with persistent asthma
compared to those with exercise-induced symptoms only. The natural history of EIA is unclear
and may be different for elite athletes. Leukotriene biology has helped the understanding of
EIB. The type and intensity of exercise are important factors for EIB. Exercise participation
is necessary for proper development and control of EIA is recommended. Symptoms
of EIB should be confirmed by proper testing. Biologic markers may also be helpful in
diagnosis. Not all exercise symptoms are from EIB. Many medication and nonpharmacologic
treatments are available. Asthma education is an important component of managing EIA.
Many medications have been tested and the comparisons are complicated. Montelukast is a
US Food and Drug Administration-approved asthma and EIB controller and has a number
of potential advantages to other asthma medications including short onset of action, ease of
use, and lack of tolerance. Not all patients improve with montelukast and rescue medication
should be available.
Keywords: exercise, asthma, montelukast, Singulair, bronchospasm, leukotrienes

The use of the term “exercise-induced asthma” (EIA) began during the 1960’s.1
Subsequently the terms “EIA” and “exercise-induced bronchospasm” (EIB)
are often used interchangeably. 2 However, EIB specifically denotes the reduction in lung function after a standardized exercise test. 1,3,4 “Exercise-induced
bronchoconstriction” is another term that has been used in the literature.5 Some
clinicians/authors use EIA to describe individuals with known asthma who have
bronchoconstriction during exercise.6–8 However, some use EIA to describe patients
that have bronchoconstriction only during exercise, and use EIB to describe patients
with asthma that have bronchoconstriction with exercise.9 Therefore, the use of the
terms “EIA” and “EIB” in the literature is unclear.1 For this review I will use the
term EIB primarily to indicate bronchospasm with decreased pulmonary function
testing following exercise and EIA to indicate those patients with asthma difficulties
associated with exercise.
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Overview
Asthma and allergic rhinitis are closely associated with EIB
and are the most common chronic diseases affecting US
children.10 The prevalence of asthma is increasing11 as is EIA.4
Exercise is a common trigger for asthmatics, and for some, it is
the only trigger.12,13 EIA affects patients in all levels of asthma
severity, but perhaps with higher prevalence in children with
asthma14 and many are recognized as having asthma features
at rest.15 Asthma is heterogeneous16 and EIB is likely also
heterogeneous. The predominant symptoms of EIA are cough,
wheeze, shortness of breath, and chest discomfort associated
with exercise.12 The physical examination may be normal or
consistent with asthma.12 The likelihood of different forms
of exercise causing asthma symptoms is often referred to its
“asthmagenicity.”12 For instance, for most asthmatics running
is more likely to cause EIA than swimming. More intense
exercise is also more likely to lead to asthma symptoms especially if not preceded by a warm-up exercise (see subsequent
section on nonpharmacologic treatment of EIB).
EIB may be the result of an overall lack of asthma
control13,17 and a professional athlete with EIA has a form of
occupational asthma18 impairing performance.19 Exercise is
the most common trigger of bronchospasm in children with
asthma3,12 and worsens quality of life and limits activity.15,20–22
Interestingly, the lungs and airways do not respond to exercise
training by increasing their capacity similar to the peripheral
muscles and the cardiovascular system.4 After experiencing
a significant EIA event, future exercise-related activities
may be limited19 and parents of children with asthma have
been shown to intentionally or inadvertently restrict their
child’s activity.22 In children with mild-to-moderate asthma,
exercise limitation is a primary complaint17 and EIA may
interfere with activities important for physical and social
development.22–25 Vilozni and colleagues documented EIA
in children as young as three years old.21
Regular physical activity is important to health and
well-being. Full participation in sporting activities is one of
the important goals of asthma management.3,13,22,26 Moderate
exercise has been shown to stimulate the immune system.27
Physical activity is a significant component of daily life in
childhood and adolescence, so for those affected with EIA it
can be an equally significant problem.3 Children and young
adults with asthma are more affected by EIB than adults with
asthma and therefore EIA is more common for them perhaps
because of their increased levels of physical activity.25,28,29
Poor perception of EIA symptoms is common and the child
may fail to notice the symptoms and others may not take note
of the limited performance.21,22
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The natural history of EIA is unknown. Does asthma
resolve if a patient with EIA stops exercising? Does lung
function decline more rapidly in a patient with EIA who
continues to exercise?18 These questions remain unanswered.
While this is only a brief overview, more comprehensive EIA
reviews and guidelines are available.12,30

EIA pathogenesis
In EIB, the airway epithelium is likely disrupted and along
with inflammatory cells may be the basis of EIB31 (Table 1).
EIB may represent a distinct phenotype31 and EIB pathogenesis
in a chronic asthmatic may be from a different mechanism
than a person who only has asthma symptoms with exercise.32
Exercise provides multiple stimuli to induce bronchospasm
and hyperpnea is thought to be dominant.33 Endurance
events appear to be higher risk for developing EIB19,34 and
the literature remains unclear regarding whether a late-phase
response occurs in EIB.35
Hyperpnea induces bronchoconstriction through water
loss in the “osmotic hypothesis” or airway cooling in
the “heat-loss hypothesis.”3,4,12 Because asthma is more
common in swimmers compared to other sports, some have
suggested a pool chlorine hypothesis as an explanation.36–38
However, asthmatics may tolerate swimming better than
other activities36 and swimming is considered a beneficial
whole body exercise.37 Ice rink-related athletes are thought
to be at higher risk of EIB from airborne ultrafine particulate
matter released by ice-resurfacing machines.4
Exposure to cold air, allergens, chlorinated pools, or high
levels of pollutants may sensitize or irritate the airways.34
Risk factors for EIB include family history of atopy, positive
skin prick testing, allergic rhinitis and eczema39 as well as
others and have been reviewed in other works.12 Atopy is a
major risk factor for EIB in some and controlling rhinitis
may improve asthma control.19 Exposure to indoor allergens
is a risk factor for EIA and immunotherapy is a protective
factor.33 Some studies have shown elite athletes to be at
higher risk of atopy,8 but some studies have shown that
elite athletes are not at higher risk of allergic sensitization.26
Children with human immunodeficiency virus and treated
with highly active antiretroviral therapy (HAART) have an
increased risk of asthma.40
Table 1 Pathogenesis hypotheses
Osmotic-water loss
Thermal-heat loss
Pool chlorine
Airway sensitization-chemical mediators
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Chemical mediators of an inflammatory cascade including
histamine, prostanoids, and leukotrienes are thought to be
central in the pathogenesis of EIA.3 Of note specifically to
this review, the levels of cysteinyl leukotrienes are elevated
after exercise in asthmatics with EIB.31 Also, eosinophils
with a hyperosmolar stimulus generate and release cysteinyl
leukotrienes.41 Eosinophil levels in blood and sputum have
been correlated to the presence and severity of EIB.41 The
serum concentration of eosinophil cationic protein (ECP),
a cytotoxic protein causing desquamation and bronchial
epithelial destruction with bronchial hyperactivity, is also
higher in asthmatic children with EIB after exercise.42 Overall,
further research in the causation of EIA is needed.7

Confirmation testing
Exercise tests are commonly utilized to confirm clinical
concerns of asthma in children39 and history of symptoms
alone is not adequate to diagnose EIB.13,32 The American
Thoracic Society and the European Respiratory Society
published guidelines for pulmonary function testing
including specific statements for preschool children. 43
Exercise testing has been specifically addressed as well.44
Patients with near-normal airway function at rest may still
have significant EIA that limits their ability to exercise.15
Airway hyperresponsiveness to exercise suggests a lack of
asthma control45 and female athletes have greater airway
hyperresponsiveness than male athletes.46
EIB challenges are subdivided as direct or indirect
with direct challenges acting on airway smooth muscle
receptors and indirect challenges reflecting the degree of
airway inflammation.6 Methacholine challenge is the most
commonly used direct test.34 Indirect tests include exercise,
eucapnic voluntary hyperpnea (EVH; also known as
isocapnic hyperventilation test), and hyperosmolar aerosols
such as hypertonic saline and mannitol acting through the
release of mediators.34
An exercise challenge is done to reproduce a patient’s
symptoms and signs and to document pulmonary function
changes to confirm or refute the diagnosis of EIA. 12
A 10%–20% reduction in forced expiratory volume in one
second (FEV1) or peak expiratory flow (PEF) following
exercise and an improvement with a bronchodilator is
consistent with EIB.12 Exercise challenges are expensive,
require significant space, are complex and time intensive,
as well as uncomfortable for patients.29,47 A free running test
is the most familiar, most asthmagenic, and least expensive
exercise challenge47,48 and therefore most convenient.21
Inhaling cold, dry air has been shown to be EIB’s most
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potent trigger.3 Impulse oscillometry can be used to detect
EIB in young children39 and EVH may overdiagnose EIB.47
The coding and billing for physician services related to EIB
testing is reviewed by Pohlig.47

Surrogate tests and biologic markers
Biologic markers measured from the lungs may reflect
more accurately EIB related changes compared to other
biologic fluids such as urine and blood from less systemic
dilution.28 The main mediator of neural (nonadrenergic
noncholinergic) bronchodilation is thought to be nitric oxide
(NO).14 In 20 asthmatic children, Nishio and colleagues
found that exhaled NO (eNO) was significantly higher in the
EIB-positive group than in the EIB-negative group evaluating
fall in FEV1 and forced expiratory flow (FEF)25%–75% following
bicycle ergometer exercise testing.49 Lex and colleagues
studied 85 children with atopic asthma aged 5–16 years
and found EIB was not seen with eNO  25 ppb and that
symptom questionnaires were almost as reliable as eNO at
ruling out EIB.29 Carraro and colleagues evaluated 19 children
aged 7–18 years with asthma compared to 14 healthy
controls using a treadmill exercise test.28 Those with EIB
were treated with montelukast for three days and testing
was repeated. Measurements of exhaled breath condensate
levels of cysteinyl leukotrienes, leukotriene B4, ammonia
concentrations, and fraction of eNO were obtained. EIB
patients had higher levels of cysteinyl leukotrienes at baseline
compared to non-EIB patients and controls. After three days
of montelukast, cysteinyl leukotriene levels decreased by a
statistically nonsignificant amount and no significant change
was noted in fractional eNO either. However, maximal fall
in FEV1 did show improvement. In the overall group of
children with asthma, the maximal post-exercise fall in FEV1
correlated with the cysteinyl leukotriene level. 8-isoprostane,
an oxidative stress marker derived from the free radicalcatalyzed peroxidation of arachidonic acid on plasma
membrane phospholipids was measured in the exhaled breath
condensate of 46 children and adolescents and baseline levels
were higher in the EIB group.14 A direct role for chemokines
in EIB was not observed in childhood asthma.50

Treatment
Overall asthma management in athletes is similar to
nonathletes with asthma.34 EIB can be the initial symptom
trigger of asthma and the last to resolve with medication.1
Exercise tolerance is one of the important measures of
asthma control and therefore should be monitored by
exercise testing.19,33 Asthma medication costs are a large
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part of asthma expenditures.51 Many medications have been
used in the treatment of EIA and have included albuterol,
salmeterol, formoterol, montelukast, ipratropium bromide,
calcium channel blockers, inhaled furosemide, theophylline,
cromolyn, nedocromil, and inhaled corticosteroids.8,19,23–25,48
Choice between these agents is based on onset, efficiency,
safety profile, ease of use, compliance, cost, and duration
of action.12,13,16,52
Asthma education to develop and improve self management
skills should be included in overall asthma management.22,30
Unfortunately, school policies may not facilitate asthma
management and may lead to opting out of exercise.22
Parents, children, teachers, coaches, and trainers require
asthma education regarding exercise participation, asthma
medication adjustment, and how to distinguish between
normal physiologic and asthma exercise limitations.22

Therapeutic use exemptions
Some have been concerned that athletes without asthma have
also been using β2-agonists.34 Doping is defined as the use
of forbidden substances and methods intending to improve
an athlete’s performance. The World Anti-Doping Agency
has a prohibited list of medications as well as therapeutic
use exemptions for medications including β2-agonists and
glucocorticosteroids.53 From 2003–2008, 868 therapeutic
use exemptions for β 2-agonists were received by the
International Association of Athletics Federations and 80%
were approved.34 No ergogenic effects of inhaled β2-agonists
or inhaled steroids have been demonstrated.8 β2-agonists and
inhaled corticosteroids are not thought to improve an athlete’s
performance outside of improving asthma control.4 The use
of inhaled β2-agonists by athletes has increased and perhaps
were previously underused.34 The International Olympic
Committee has recommended a diagnosis based on symptoms
be confirmed with pulmonary function testing.34

Nonpharmacologic treatment of EIB
Reducing asthma trigger exposures and warm-up pre-exercise
is important in preventing EIB.1,11,30 Breathing through the
nose during exercise1 and a face mask when exercising in cold
air may be helpful.8,19,34 A cool-down exercise may also be
helpful in reducing EIB episodes.1,19 Aerobic exercise training
reduced bronchial hyperresponsiveness and the improvements
were enhanced with concomitant montelukast.54 Patients with
EIA should be cautioned not to exercise when their asthma
is not under control.12
Avoiding training in suboptimal environments should
reduce airway penetration of harmful factors during the high
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ventilation demands of intense exercise.34 Also reducing
chlorine derivatives in swimming pools, ozone, and particulate
matter may also be helpful in preventing EIB.34 Allergen
avoidance in sensitized individuals is recommended.8 Diet
may also influence EIB32 and increasing components such as
omega-3 polyunsaturated fatty acids and antioxidant intake
as well as reducing sodium may be helpful.8 Increasing
vitamin C intake may decrease EIB as well.32

Precautions
The differential diagnosis of EIB has been reviewed in
multiple studies.4,8,12 Not all dyspnea associated with exercise
is from EIB12 and not all dyspnea when exercising in cold
air is asthma either.55 For instance exercising in a cold
environment reduces exercise capacity independent of EIB
although the cold environmental conditions aggravated the
effects of EIB.56

Leukotriene biology
Exercise physical stress induced transcriptional changes,
specifically in the leukotriene pathway have been shown
to be enhanced following exercise and may play a role in
EIB.2 Concentrations of cysteinyl leukotrienes are higher in
asthmatic children with EIB3 and are thought to mediate the
immediate reduction in airway caliber.20 Leukotrienes are a
family of polyunsaturated eicosatetraenoic acids formed from
the phospholipid layer.11 The two classes of leukotrienes are
cysteinyl (LTC4, LTD4, LTE4) and noncysteinyl (LTB4).11 The
cysteinyl leukotrienes all contain a thioether-linked peptide:
glutathione in LTC4, cysteinyl-glycine in LTD4, and cysteine
in LTE4.51
Cysteinyl leukotrienes are derivatives of the 5-lipoxygenase
pathway of arachidonic acid metabolism and are one of the
important mediators of airway inflammation including a
role in the pathogenesis of EIA.3 Phospholipase A2 catalyzes
the release of arachidonic acid from membrane phospholipids
and the subsequent enzyme actions are reviewed by Riccioni
and colleagues. 2,51 The cysteinyl leukotriene synthesis
pathway requires a series of sequential enzyme actions
from 5-lipoxygenase, 5-lipoxygenase-activating protein,
and leukotriene C4 synthase.57 Chromosome 5q35 encodes
for the key enzyme leukotriene C4 synthase which converts
leukotriene A4 to C4.57 Cysteinyl leukotrienes are released
from activated inflammatory cells including mast cells
and eosinophils,3,41 basophils,58 neutrophils, macrophages,
epithelial cells, and vascular endothelial cells.11
Cysteinyl leukotrienes act on type I (Cys-LT1) receptors
as a pro-inflammatory mediator with numerous local and
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systemic effects including bronchoconstriction and increased
airway hyperresponsiveness, decreased activity of respiratory
cilia, increased mucus secretion, increased venopermeability
with plasma exudation, vasoconstriction, promotion of
eosinophil migration into the airway mucosa, and airway
smooth muscle proliferation.3,23,57–60 The Cys-LT1 receptor
gene maps to the X chromosome.57 Leukotrienes are 100
to 1,000 times more effective than histamine in inducing
bronchospasm,3,59 and were previously known as the slowreacting substance of anaphylaxis.23 Ten to 20% of cysteinyl
leukotrienes produced are released into the urine.3 In asthmatic
patients, the urinary excretion of leukotriene E4 increases after
exercise.61 Even high doses of oral steroids do not change
urinary or airway secretion concentrations of leukotrienes.11

Pharmacology, mode of action,
and pharmacokinetics of montelukast
Clinical pharmacology/biochemistry
of montelukast
Montelukast is rapidly absorbed following oral administration
with peak plasma concentrations in 2.6–4 hours and a mean
bioavailability of 58%–73%,3,59 which is generally noted to
be higher in chewable tablets.59 No dose-response relationship
was observed down to a 10 mg once daily dose in adults and
the children’s dose was chosen to provide a similar overall drug
exposure anticipating similar efficaciousness.59 Absorption
and pharmacokinetics is not much affected by meals or by
the time of day administered, respectively.59,60 Steady state
was reached on day 2 of administration.59 The mechanism
of action is through high affinity and selectively binding to
the Cys-LT1 receptor without agonist activity.62 Gender and
advanced age do not significantly influence montelukast
pharmacokinetics.59,62 Montelukast is extensively bound
to plasma proteins with a volume of distribution average
of 8–11 liters, minimal distribution across the blood–brain
barrier, and minimal tissue concentrations 24 hours after
administration.59,62 Montelukast is extensively metabolized
in humans and is similar in pediatric and adult subjects.59
Metabolites are excreted in bile with minimal amounts in
plasma and 0.2% recoverable in urine.59
Once daily dosing at bedtime was chosen based on
higher plasma levels at night when the circadian variation
for asthma-related airway obstruction tends to be worse59 and
when there may be a higher concentration of alveolar-tissue
CD4+ lymphocytes.63 Pajaron-Fernandez and colleagues
found no statistical difference in exercise challenge results
when comparing morning vs evening montelukast dosing
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in 24 children aged 6–14 years, but showed better outcomes
in some children with evening dosing.63 Medication-induced
tolerance to the bronchoprotective effect over time has not
been noted.3

Singulair overview
Singulair (Merck & Co., Inc., Whitehouse Station, NJ, USA)
is an orally active, selective leukotriene receptor antagonist
medication for treating asthma and allergic rhinitis.3,62
Montelukast may also inhibit 5-lipoxygenase.2 Both single
and multidose studies in adults and children have shown
protection against EIA.3 Singulair is available in multiple
oral formulations including a 10 mg film-coated tablet,
4 mg and 5 mg chewable tablets, and 4 mg oral granules.3
Singulair is administered 10 mg once daily to adults, 5 mg
once daily to children aged 6–14 years, and 4 mg once
daily to children aged 2–5 years for asthma treatment.59,62 In
April 2007, the US Food and Drug Administration (FDA)
approved montelukast as a single-dose preventative for EIB
in patients aged 15 years or older.17 The response to asthma
medications is variable,16 including montelukast.32 Predicting
by genotype which patients will be poor or better responders
to montelukast has been studied,57,64,65 but no clear clinical
recommendations have been made.

Efficacy studies in children,
adolescents, and adults
Complications in reviewing studies
Comparisons of the outcomes of studies evaluating the
effectiveness of montelukast is complicated by many factors
including the inclusion criteria of the studied group, particularly
how the authors defined EIA and/or EIB. Other specific
variations include age of the patients, subtype of asthma
(eg, EIA only, intermittent, severity class of persistence),
concomitant medications allowed (eg, inhaled corticosteroids,
long- and short-acting β2-agonists, antihistamine), control
at the time of the exercise challenge(s), aspirin sensitivity,
severity of the allergic component, overall diet (eg, caffeine
intake, omega-3, vitamin C), seasonal changes over the study
period, as well as others were found in reviewing the studies.
The end points and the comparisons made were also variable.
Protocols of timing (eg, relative to medication dosage, time
of day) and type of exercise challenge (treadmill, bicycle,
free running) and duration of dosing were also variables
making comparisons difficult. Small numbers involved in
many studies led to limitations.
Various measurements have evaluated the effectiveness of
EIB prevention. These measurements have included: reduction
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in the area under the FEV1 curve, the maximal decrease in
post-exercise FEV1, time from the maximal decrease in FEV1
to return to within 5% or 10% of pre-exercise values, number
of patients who required β2-agonist rescue, asthma symptom
score, and percentage of those protected. No end point is
considered clearly the best. Many studies that used more than
one end point sometimes found statistical significance with
one or some, but not all end points. Some have suggested that
an improvement in percentage decrease in FEV1 of 50% or
greater relative to placebo-related decrease can be defined as
clinically significant.61 In the following themed comparisons,
I have arranged most of the studies chronologically.

Montelukast compared to placebo
Bronsky and colleagues studied 27 patients by exercise
challenge 20–24 hours and 32–36 hours after montelukast
0.4 mg up to 50 mg vs placebo.58 They found montelukast
10 and 50 mg protected against EIB compared to placebo
at 20–24 hours post-dose and only slight nondose-related
effects were observed at 32–36 hours post-dose. Kemp and
colleagues compared montelukast to placebo in 27 children
aged 6–14 years and found improvements in EIB in the
montelukast group.23 In a 12-week study, Leff and colleagues
compared montelukast to placebo in 110 patients aged
15–45 years by treadmill exercise challenge and found EIB
protection with montelukast.45 No protective or rebound
effects were found two weeks after treatment was stopped.
Melo and colleagues studied 22 patients with a mean
age of 12.6 years on a stationary bicycle and found less
deterioration in lung function with montelukast compared
to placebo including a late phase response in the minority of
patients with a dual response.35 Kim and colleagues enrolled
64 children aged 8–14 years to compare eight weeks of
montelukast to placebo in an outdoor free running challenge
and found the asthma symptom score significantly improved
for the montelukast group.48 This improvement persisted
after an additional eight weeks of placebo. de Benedictis
and others studied 32 children aged 6–12 years for four weeks
to compare montelukast to placebo by exercise challenge at
days 3, 7, and 28 and found improvement with montelukast
independent of concomitant inhaled steroids and without
evidence of tolerance.66
In their study of almost 50 patients, Pearlman and
colleagues showed improvement in protection from EIB
by exercise challenge at two, 12, and 24 hours after dosing
with a single dose of montelukast compared to placebo.61
However, in their study of 19 patients aged 7–13 years Peroni
and colleagues found protection with montelukast vs placebo
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with exercise challenge at 12 hours, but not at two or 24 hours
following single-dose therapy.24 These authors point out that
the dose of montelukast was received in the morning, that
all study patients were on inhaled corticosteroids, and that a
placebo effect has been documented. In a Merck-supported
study by Philip and colleagues, montelukast was compared to
a placebo in a group of patients aged 15–45 years two hours
after a single dose using a treadmill exercise challenge and
found significantly more patients receiving montelukast
were protected from EIB.67 This protection was also noted
at 12 and 24 hours postdose.

Montelukast compared
to long-acting β2-agonists

In a Merck grant-supported study by Villaran and colleagues,
197 patients aged 14–45 years were evaluated to compare
montelukast and salmeterol over an eight-week time frame
and improvements in both treatment groups was found,
but montelukast had the greater effect.68 Patients treated
with concomitant inhaled corticosteroids showed the same
effect as those not on inhaled corticosteroids and tolerance
to bronchoprotection was not prevented by concomitant
inhaled corticosteroids. In a Merck-funded trial, Edelman
and others studied 177 patients aged 15–45 years to compare
eight weeks of montelukast to salmeterol.15 Within three days
both groups showed EIB improvements. However, a loss of
bronchoprotective effect was noted in the salmeterol groups
at four and eight weeks whereas the montelukast effect was
maintained. Storms and colleagues compared montelukast,
salmeterol, and placebo over a four-week treatment period
in patients aged 15–45 years.69 They observed a number of
findings, including maximal post-albuterol rescue FEV1
percent-predicted values improved in montelukast and
placebo groups, but not in salmeterol with the maximum
FEV1 lowest in the salmeterol group. Patients treated with
montelukast had significantly greater alleviation of EIB compared to placebo but the salmeterol group did not. The authors
pointed out that concerns in the salmeterol group regarding
long-acting β2-agonists decreased the effects of short-acting
β2-agonists and tachyphylaxis with downregulation of
airway smooth muscle receptor numbers. Uncoupling of
intracellular signaling may occur even with concomitantly
administered inhaled corticosteroids. Steinshamm and
colleagues compared montelukast to salmeterol in 18 adults
with EIB and concluded that montelukast has a favorable
effect on gas exchange at moderate exercise compared to
salmeterol.70 They also pointed out the suggestion that regular
use of salmeterol leads to a decrease in rescue response

Journal of Asthma and Allergy 2009:2

Journal of Asthma and Allergy downloaded from https://www.dovepress.com/ by 23.112.138.152 on 21-Sep-2021
For personal use only.

Dovepress

to short-acting β2-agonists after exercise. Salmeterol and
formoterol provide EIB protection after a single dose for
up to 12 hours but their protective duration lessens when
given regularly.61 In a Merck protocol, Philip and colleagues
compared single-dose montelukast or salmeterol in
47 patients aged 14–45 years by treadmill exercise challenge
and found significant EIB protection within two hours of
dosing and duration of at least 24 hours for montelukast.52
The efficacy was similar in a magnitude to 50 µg of inhaled
salmeterol with a longer duration. Stelmach and colleagues
studied 91 patients aged 6–18 years with EIB and allergies
comparing budesonide/formoterol, budesonide/montelukast,
montelukast, budesonide, or matching placebo for eight
weeks. They found the protective effect against treadmill
exercise challenge better with montelukast and budesonide/
montelukast by comparison.9 They recommended that
montelukast should be added to control EIB in children even
if on low-dose inhaled steroid therapy.
The International Olympic Committee and others
recommend against using LABAs as monotherapy.11,30,34 In
an editorial by Dr Miles Weinberger, he states “clinicians
would be wise to add LABAs selectively…so as to identify
the occasional patient in whom the induced tolerance results
in decreased clinical response to the β2-agonist inhaler that
the patient uses for rescue and before exercise.”71 Szefler has
made similar recommendations.40

Montelukast compared
to short-acting β2-agonists

Raissy and colleagues studied 11 patients 7–17 years
old with mild asthma with a treadmill exercise challenge
comparing 3–7 days of montelukast or placebo with
albuterol MDI pre-exercise and found the albuterol superior in preventing EIB.17 Hancox and colleagues evaluated
a group of patients aged18–50 years with EIB by treating them with salbutamol or matching placebo for one
week and found those treated with scheduled salbutamol
had worsened EIB after dry-air cycle ergometer exercise
challenge.72 In addition, the FEV1 remained significantly
lower throughout the post-exercise salbutamol doseresponse rescue in those treated with scheduled salbutamol.
The authors were concerned that patients with EIA treated
with regular or frequent β-agonist medications will have
worsening exercise symptoms and a reduced response
to β-agonist rescue. The frequency, dose, and duration
to develop these effects are unknown. A combination of
receptor downregulation and proinflammatory mechanisms
were postulated as causes.
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The International Olympic Committee has stated that
although “β2-agonists are likely to remain the most effective
bronchodilators available in the foreseeable future” they
“should be reserved for occasional use and breakthrough
symptoms.” 30 Tolerance to β 2-agonists, usually only
partial, is a concern, increasing the airway sensitivity to
bronchoconstriction to exercise and allergen stimuli.34 The
International Olympic Committee and others recommend
against regular/frequent short-acting β2-agonist use as sole
therapy for athletes with asthma.34

Montelukast compared to mast
cell stabilizers
A study by Lecheler and colleagues compared a fixed
combination of disodium cromoglycate plus reproterol
(DSCG/REP) to montelukast in a group of children aged
11–18 years and found that DSCG/REP before exercise
was superior in preventing EIA.73 Significant limitations in
this study are noted including small numbers and an open
design among others.

Montelukast compared
to inhaled corticosteroids
Vidal and others compared montelukast to budesonide in
20 patients with EIA and found that budesonide provided
improved protection to exercise challenge on a treadmill
compared to montelukast in 16 patients (80%), but better
protection with montelukast in the remaining four patients
(20%).20 They concluded with the recommendation that
both medications be tested in each patient prior to the final
decision. Formoterol combined with budesonide was similar
to budesonide alone suggesting little additional effect after
eight weeks of treatment.9

Montelukast compared with loratadine
Peroni and colleagues compared placebo, loratadine,
montelukast, and combination montelukast and loratadine in
a single-dose test in 19 allergic-asthma children and found no
statistically significant additive effect using the combination
compared to montelukast alone.74 H1-antihistamines have
been found to have minimal EIB effects.19

Montelukast compared
to other leukotriene modifiers
Zileuton, a 5-lipoxygenase inhibitor; MK-571, pranlukast,
cinalukast, zafirlukast leukotriene receptor antagonists;
and iralukast, an LTD4/LTE4 antagonist have produced
both subjective and objective improvements in asthma
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patients.19,23,48,75 Coreno and colleagues compared salmeterol,
montelukast, zafirlukast, zileuton, and placebo in 10 patients
using a cycle ergometer and breathing frigid air and found
that all of the leukotriene-modifying drugs inhibited EIA
however zileuton was less potent and shorter acting.76

associated with zafirlukast so monitoring liver function
has been recommended. 60 Post-marketing experiences
have further documented potential side effects including
a relatively recent report of an adolescent patient suicide
while treated with montelukast.40,62

Montelukast in aspirin-sensitive patients

Clinical usage based on patientfocused perspectives
and clinical data

Aspirin sensitive asthmatics are characterized by cysteinyl
leukotriene overproduction and excrete high amounts in
their urine.77 They have overexpression of LTC4 synthase on
bronchial biopsy and a variant of allele C is more common in
severely effected aspirin-sensitive patients.77 Mastalerz and
others studied 19 aspirin-sensitive asthmatics by exercise
challenge and found that a single dose of montelukast
attenuated or prevented EIB in the majority compared to
placebo.77

Montelukast limitations/concerns/
safety/tolerability
Not all patients taking montelukast are protected from EIA,3
with protection ranges typically from 50%–80%.48 As noted
previously in the Singulair overview section, no biologic
markers clearly identify antileukotriene medication responders
from nonresponders.3 The 4 mg and 5 mg preparations contain
phenylalanine and patients with phenylketonuria should avoid
them.62 Treatment of airway inflammation with ICS has been
shown to improve oxygenation and exercise performance due
to increased alveolar ventilation and improved pulmonary gas
exchange efficiency.78 Similar studies with montelukast are
not found in the literature.

Side effects
Most studies suggest leukotrienes receptor antagonists
are well tolerated11 and montelukast is rated pregnancy
category B by the US FDA.60,62 It is unknown if montelukast
is excreted in human milk.62 No evidence of dose-limiting
toxicity has been noted.59 Montelukast was not associated
with growth rate reduction as has been seen in inhaled
corticosteroids.11 No clinically important drug interactions
with montelukast have been identified. 59,60,62 However
zileuton may affect other drugs’ metabolism and also has
been associated with liver dysfunction.60 Churg–Strauss
syndrome has been associated with zafirlukast, but not
montelukast.11 Physicians are recommended to remain alert
for eosinophilia, vasculitic rash, and other symptoms.62
Montelukast has a wide safety margin with no dosage
adjustment for renal insufficiency or for mild to moderate
hepatic insufficiency.59 Liver dysfunction has also been
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Approximately one third of all maintenance therapy
prescriptions for asthma are for leukotriene inhibitors
thought to be related to ease of use and dosing, lack of side
effects, and efficacy60 (Table 2). Montelukast can be used
intermittently since effectiveness is noted after a single
dose.3 However, it may be best suited as a daily controller
for patients with poor inhaler technique or poor compliance,
patients concerned with inhaled steroid effects, or patients
with EIB, especially if they continue to have inadequate
protection from short-acting β2-agonists.16,60 Some clinicians
use montelukast particularly for children with activity levels
that are frequent, but at irregular intervals3,7 throughout the
day, which makes it hard to anticipate pre-exercise β2-agonists
and perhaps leading to regular and too frequent usage.61
Given that regular β2-agonists adversely affects EIB, some
clinicians suggest that they be “prescribed with care particularly in patients with prominent exercise symptoms.”72 As a
guideline, some authors have suggested that those with EIA
more than once or twice a week might benefit with use of an
anti-inflammatory treatment.20
Inhaled corticosteroids have been shown to be more effective
than montelukast in several measures of asthma control,16
but this may be different in regards to EIB. Increasing from
a low dose of an inhaled corticosteroid for uncontrolled
asthma results in marginal improvement in efficacy and
may lead to unwanted side effects. Adding a long-acting
β2-agonist or leukotriene receptor antagonist to improve
control is recommended.69 In EIA patients, montelukast may
be advantageous to long-acting β2-agonist add-on therapy.69
Table 2 Montelukast advantages
Large treatable age range and multiple dosing forms
Once a day
Taken by mouth, easy to swallow or a tasty chewable
Improves EIB in the majority of patients
Lack of tolerance
Good safety profile
Abbreviation: EIB, exercise-induced bronchospasm.
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The ease of a daily oral tablet at bedtime encourages
adherence compared to other asthma medications. 10,16,20
In addition, the choice to use long-acting β2-agonist as
add on treatment for asthma control may adversely affect
EIA.69 Lastly the lack of tolerance may make montelukast
preferential to others.3 Neither montelukast nor salmeterol provided complete bronchoprotection and therefore
prophylactic use of a short-acting β2-agonist may be necessary15 and should be available for breakthrough symptoms.
Finding the individually correct therapeutic balance of
efficacy, tolerability, adherence, and ease of use is left to the
clinician and caregiver to achieve.16

Conclusions
EIA is an important clinical disease for patients young and old.
The pathogenesis of EIA remains uncertain, but the biology
is becoming more clearly understood. Patient symptoms lead
the clinician to provide confirmatory testing and treatment.
Many treatment options are available and extrapolating
study data to an individual patient is complicated. Clinically,
montelukast is a helpful medication for many patients with
EIB and is typically well tolerated.
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